In a first aspect, the present invention relates to genetically modified T-cells having a chimeric antigen receptor (CAR) in a method for adoptive cell therapy for treating TOSO+ cancer, like B-cell leukemia/lymphoma, in a subject in need thereof. In particular, the present invention relates to a genetically engineered T-cell containing and expressing a specific chimeric antigen receptor being toxic to TOSO+ cancer cells while being less toxic or non-toxic to TOSO+ non-cancer cells, in particular, being non-toxic to normal B cells and its precursors. In a further aspect, the present invention relates to a specific chimeric antigen receptor and the nucleic acid molecule encoding the same as well as vectors and cells containing the same.
